The Genetic Education for Men (GEM) Trial: Web-Based Genetic Education vs. Standard Care in Men From Hereditary Cancer Families
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 63
- 试验地点
- 2
- 主要终点
- Completion of BRCA1/BRCA2 Gene Testing
研究概览
简要总结
The primary goal of this research is to develop and test a web-based genetic education/counseling intervention. This intervention is designed to educate men from hereditary cancer families about the personal relevance of genetic testing in order to help them make decisions about whether to pursue genetic testing. The investigators will test this intervention against standard care for men from hereditary cancer families. The web-based educational intervention includes all of the information typically covered during genetic counseling. As a result, after completing the education intervention participants can proceed directly to genetic testing if they choose. The investigators will conduct a survey prior to randomization and then follow-up surveys at 1-month and 6-months post-randomization. The primary outcome will be uptake of genetic testing. Secondary outcomes will be completion of genetic counseling and decision satisfaction.
详细描述
Aim 1: Develop a web-based intervention to increase genetic counseling/testing uptake in men at high risk for carrying a BRCA mutation.
Aim 2: Evaluate the impact of the web-based intervention (WI) vs. usual care (UC)
Aim 3: Examine the behavioral and psychosocial impact of BRCA testing in men from BRCA families.
Identification and Recruitment of Subjects. Participants will be recruited via the Lombardi Comprehensive Cancer Center's Familial Cancer Registry and the Non-therapeutic Subject Registry Shared Resource. These registries contain over 800 female BRCA1/2 positive participants. In addition, the investigators will recontact participants from prior trials who have consented to be recontacted for future research and will accept self-referred index cases who contact the study about participation. Female index cases will be identified based on vital status, recency of contact, and availability of test reports documenting their positive BRCA1/2 status. Where available, pedigrees will also be reviewed.
To protect the privacy of study participants, participants will be recruited through their female BRCA mutation carrier relatives (index patients) who will provide their contact information. The investigators will identify adult female mutation carriers who are enrolled in the Non-therapeutic Subject Registry Shared Resource, Familial Cancer Registry, who received a positive test result as a participant in IRB 2004-133 and provided consent to be contacted about future research studies or who contact the study directly about enrollment. The study staff will mail a study invitation to potentially eligible index cases. This mailing will include: an introductory letter; an informed consent document; a HIPAA Authorization form; study brochures for distribution to male relatives if desired; and a family contact form requesting contact information and current ages for potentially eligible male relatives. The investigators will request that index patients return the Family Contact Form in a self-addressed stamped envelope or complete an electronic version of the form. Consistent with prior research and Institutional Review Board guidance, the letter and Family Contact Form will reiterate that index patients should request permission from their potentially eligible male relative(s) prior to providing contact information to us, and the index patient's signature on the Family Contact Form will attest to this. The packet will also contain information on how women may decline participation (an opt-out post card). If, after 2-3 weeks, individuals do not decline participation, a research assistant will call to determine interest in the study and request completion of the Family Contact Form.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 70 Years(Adult, Older Adult)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •At least one first-, or second--degree relative who has been found to carry a BRCA1 or BRCA2 mutation.
排除标准
- •Personal diagnosis of any cancer, other than non-melanoma skin cancer
- •Prior genetic counseling or testing for hereditary breast/ovarian cancer
- •Family history suggestive of a hereditary cancer syndrome not attributable to the BRCA1 or BRCA2 mutation in their family, based on pedigree review by the study team
- •An uncertain risk of carrying the familial BRCA1 or BRCA2 mutation (e.g., because it is not clear on what side of the family the mutation is segregating), based on pedigree review by the study team
- •Have one one or more children who are BRCA1 or BRCA2 positive
- •Cannot participate in or understand English
- •Cannot provide meaningful informed consent
结局指标
主要结局
Completion of BRCA1/BRCA2 Gene Testing
时间窗: 6-months
The number of participants in each arm who choose to be tested for the BRCA1 or BRCA2 mutation that has previously been identified in their family.
次要结局
- Decision Satisfaction(6-Months)
- Decision Conflict(6-Months)
- Completion of Genetic Counseling(6-months)
研究者
Marc D Schwartz
Professor of Oncology, Associate Director for Population Science
Georgetown University
